Inhaled β-agonist does not modify sympathetic activity in patients with COPD

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Haarmann, Helge ^a   Mohrlang, Cordula ^b   Tschiesner, Uta ^b   Rubin, David B ^e   Bornemann, Thore ^a   Rüter, Karin ^a   Bonev, Slavtcho ^c   Raupach, Tobias ^a   Hasenfuß, Gerd ^a   Andreas, Stefan ^a,d  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GLAXOSMITHKLINE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Specialist Lung Clinic Immenhausen   (Germany)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Beta agonist; Chronic obstructive pulmonary disease; Salmeterol; Sympathetic activity

Indexed keywords

ANTIBIOTIC AGENT; CATECHOLAMINE; GLUCOCORTICOID; PLACEBO; SALMETEROL; THEOPHYLLINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; EPINEPHRINE; NORADRENALIN; SALMETEROL XINAFOATE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; BRONCHITIS; CATECHOLAMINE BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HEART RATE; HEART RATE VARIABILITY; HUMAN; HYPERINFLATION; LUNG FUNCTION; MALE; MICRONEUROGRAPHY; MUSCLE SYMPATHETIC NERVE ACTIVITY; NEUROGRAPHY; PRESSORECEPTOR REFLEX; PULSE WAVE; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; VERY ELDERLY; ADRENERGIC SYSTEM; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PERONEUS NERVE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SINGLE BLIND PROCEDURE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; BAROREFLEX; BLOOD PRESSURE; BRAIN-DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINES; EPINEPHRINE; FEMALE; HEART RATE; HUMANS; LUNG; MALE; MIDDLE AGED; NOREPINEPHRINE; PERONEAL NERVE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULSE WAVE ANALYSIS; RESPIRATORY FUNCTION TESTS; RESPIRATORY RATE; SALMETEROL XINAFOATE; SINGLE-BLIND METHOD; SYMPATHETIC NERVOUS SYSTEM;

EID: 84931050065     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0054-7     Document Type: Article

References (46)

1. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379(9823):1341-51.
2. Sin DD, MacNee W. Chronic obstructive pulmonary disease and cardiovascular diseases: a "vulnerable" relationship. Am J Respir Crit Care Med. 2013;187(1):2-4.
3. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-61.
4. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart. 2012;98(14):1055-62.
5. Cazzola M, Page CP, Rogliani P, Matera MG. beta2-agonist therapy in lung disease. Am J Respir Crit Care Med. 2013;187(7):690-6.
6. Persson B, Andersson OK, Hjemdahl P, Wysocki M, Agerwall S, Wallin G. Adrenaline infusion in man increases muscle sympathetic nerve activity and noradrenaline overflow to plasma. J Hypertens. 1989;7(9):747-56.
7. Andreas S. Computerised Polysomnography. Thorax. 1994;49:528.
8. Weatherall M, Wijesinghe M, Perrin K, Beasley R. Long-acting beta-agonists and asthma death: how useful are different study designs to evaluate the potential association? J Asthma. 2010;47(4):434-8.
9. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175-85.
10. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009;33(5):1165-85.
11. Fatouleh R, Macefield VG. Respiratory modulation of muscle sympathetic nerve activity is not increased in essential hypertension or chronic obstructive pulmonary disease. J Physiol. 2011;589(Pt 20):4997-5006.
12. Cazzola M, Imperatore F, Salzillo A, Di Perna F, Calderaro F, Imperatore A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998;114(2):411-5.
13. Wouters EF. The systemic face of airway diseases: the role of C-reactive protein. Eur Respir J. 2006;27(5):877-9.
14. Canning BJ. Reflex regulation of airway smooth muscle tone. J Appl Physiol. 2006;101(3):971-85.
15. Heindl S, Lehnert M, Criée CP, Hasenfuß G, Andreas S. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164:597-601.
16. Raupach T, Bahr F, Herrmann P, Luethje L, Heusser K, Hasenfuss G, et al. Slow breathing reduces sympathoexcitation in COPD. Eur Respir J. 2008;32(2):387-92.
17. Macklem PT. Therapeutic implications of the pathophysiology of COPD. Eur Respir J. 2010;35(3):676-80.
18. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestation of chronic lung disease. Chest. 2005;128:3618-24.
19. van Gestel AJ, Kohler M, Clarenbach CF. Sympathetic overactivity and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Discov Med. 2012;14(79):359-68.
20. Wallin BG, Esler M, Dorward P, Eisenhofer G, Ferrier C, Westerman R, et al. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol Lond. 1992;453:45-58.
21. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54(4):690-7.
22. Delius W, Hagbarth KE, Hongell A, Wallin BG. General characteristics of sympathetic activity in human muscle nerves. Acta Physiol Scand. 1972;84:65-81.
23. Andreas S, Reiter H, Luthje L, Delekat A, Grunewald RW, Hasenfuss G, et al. Differential effects of theophylline on sympathetic excitation, hemodynamics, and breathing in congestive heart failure. Circulation. 2004;110(15):2157-62.
24. Del Colle S, Milan A, Caserta M, Dematteis A, Naso D, Mulatero P, et al. Baroreflex sensitivity is impaired in essential hypertensives with central obesity. J Hum Hypertens. 2007;21(6):473-8.
25. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996;17(3): 354-81.
26. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group Circulation. 1990;82(5):1730-6.
27. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341(8):577-85.
28. Grassi G, Seravalle G, Quarti-Trevano F, Dell'oro R. Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. Curr Vasc Pharmacol. 2009;7(2):137-45.
29. Busse WW, O'Byrne PM, Bleecker ER, Lotvall J, Woodcock A, Andersen L, et al. Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the beta2 agonist vilanterol administered once daily for 52 weeks in patients > =12 years old with asthma: a randomised trial. Thorax. 2013;68(6):513-20.
30. Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, et al. The efficacy and safety of the novel long-acting beta2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119-27.
31. Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkacova R, Bao W, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial. Pulm Pharmacol Ther. 2007;20(6):740-9.
32. Jensen MT, Marott JL, Lange P, Vestbo J, Schnohr P, Nielsen OW, et al. Resting heart rate is a predictor of mortality in COPD. Eur Respir J. 2013;42(2):341-9.
33. Castagno D, Skali H, Takeuchi M, Swedberg K, Yusuf S, Granger CB, et al. Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. J Am Coll Cardiol. 2012;59(20):1785-95.
34. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939-43.
35. Heindl S, Dodt C, Krahwinkel M, Hasenfuss G, Andreas S. Short term effect of continuous positive airway pressure on muscle sympathetic nerve activity in patients with chronic heart failure. Heart. 2001;85(2):185-90.
36. Velez-Roa S, Renard M, Degaute JP, van de Borne P. Peripheral sympathetic control during dobutamine infusion: effects of aging and heart failure. J Am Coll Cardiol. 2003;42(9):1605-10.
37. Al-Hesayen A, Azevedo ER, Newton GE, Parker JD. The effects of dobutamine on cardiac sympathetic activity in patients with congestive heart failure. J Am Coll Cardiol. 2002;39(8):1269-74.
38. Cekici L, Valipour A, Kohansal R, Burghuber OC. Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study. Br J Clin Pharmacol. 2009;67(4):394-402.
39. Guhan AR, Cooper S, Oborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. Thorax. 2000;55(8):650-6.
40. Eckberg DL. Sympathovagal balance: a critical appraisal. Circulation. 1997;96(9):3224-32.
41. Vassaux C, Torre-Bouscoulet L, Zeineldine S, Cortopassi F, Paz-Diaz H, Celli BR, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008;32(5):1275-82.
42. Barr RG, Bluemke DA, Ahmed FS, Carr JJ, Enright PL, Hoffman EA, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217-27.
43. Krieger BP. Hyperinflation and intrinsic positive end-expiratory pressure: less room to breathe. Respiration. 2009;77(3):344-50.
44. Easton PA, Hawes HG, Doig CJ, Johnson MW, Yokoba M, Wilde ER. Parasternal muscle activity decreases in severe COPD with salmeterolfluticasone propionate. Chest. 2010;137(3):558-65.
45. Gomes ME, Aengevaeren WR, Lenders JW, Verheugt FW, Smits P, Tack CJ. Improving myocardial perfusion by percutaneous coronary intervention reduces central sympathetic activity in stable angina. Clin Cardiol. 2010;33(6):E16-21.
46. Man WD, Mustfa N, Nikoletou D, Kaul S, Hart N, Rafferty GF, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004;59(6):471-6.